Table 2.

Relative Risk of Recommended 3 vs. 5-Year Follow-up in Subjects With index LRAs

		Unadjusted univariate	Multivariatea RR (95%CI)
Category	Factor	RR (95% CI)	(N=1453)	P value
Subject	Age (per 10 y)	1.04 (0.95–1.15)
	Sex
	Male	Reference
	Female	0.98 (0.86–1.12)
	Race
	White	reference	reference	.004
	Black	1.35 (1.10–1.66)	1.41 (1.14–1.75)
	Asian/Pacific Islander	1.66 (1.20–2.30)	1.72 (1.22–2.43)
	Other/multiple/unknown	0.71 (0.51–0.98)	0.73 (0.52–1.03)
	Hispanic (% yes)
	No	reference
	Yes	0.96 (0.74–1.23)
	Smoking status
	Never	reference
	Former	1.11 (0.97–1.26)
	Current	1.20 (0.96–1.51)
	BMI
	<25	reference
	25–29.9	0.91 (0.77–1.08)
	≥ 30	1.08 (0.91–1.27)
	Family history of CRC
	No	reference	reference	.01
	Yes	1.23 (1.05–1.45)	1.26 (1.07–1.48)
Exam	Indication
	Screening	reference
	Follow-up exam	1.21 (1.05–1.39)
	Diagnostic	0.98 (0.81–1.20)
	Quality of preparationa			<.0001
	Excellent	reference	reference
	Good	1.58 (1.34–1.87)	1.50 (1.26–1.78)
	Adequate	1.70 (1.31–2.21)	1.60 (1.23–2.10)
	Fair/poor	2.14 (1.66–2.75)	2.16 (1.66–2.83)
	Not stated in report	2.15 (1.77–2.60)	2.12 (1.74–2.60)
Endoscopist	Age (per 10 years)	0.90 (0.84–0.97)
	Gender
	Male	reference
	Female	0.87 (0.72–1.05)
	Specialty			.001
	Gastroenterology	reference	reference
	Internal medicine/General surgery/Other	1.41 (1.15–1.74)	1.45 (1.16–1.79)
Index findings	No. of adenomas			<.0001
	1	reference	reference
	2	1.50 (1.30–1.73)	1.47 (1.27–1.71)
	No. of serrated polyp			.0003
	0	reference	reference
	1–2	1.33 (1.15–1.55)	1.29 (1.10–1.50)
	3+	2.01 (1.50–2.69)	2.16 (1.59–2.93)
	Clinically significant serrated polypb
	No	reference
	Yes	1.31 (1.05–1.63)

BMI, body mass index; CI, confidence interval; CRC, colorectal cancer; RR, relative risk.

^aMultivariate model after removing variables stepwise with P < .05.

^bA clinically significant serrated polyp is defined as a sessile serrated adenoma, a traditional serrated adenoma, a proximal serrated polyp, or a serrated polyp ≥1 cm.